Together we RISE: Breast Cancer Awareness Month 2022

SciAni is raising awareness for one of the world’s most common cancers during Breast Cancer Awareness Month 2022. Each year in the month of October, the campaign raises awareness of breast cancer – and its significant impact. The World Health Organisation reveals 2.3 million women were diagnosed with breast cancer in 2020, with 685,000 deaths from the disease also recorded. Breast cancer screening, treatment and research are vital for improving survival rates.

The National Breast Cancer Foundation is leading the campaign with a call for universal screening: ‘This year we RISE to ensure every woman has access to the screenings she needs and the support she deserves. When we RISE, we Rally in Screening Everyone.’

We support RISE. Each year, breast cancer rates are rising by 0.5%. We believe in universal access to regular professional health screens for breast cancer is essential to stop its spread and save lives. Join us in taking the Mammo Pledge here. Check out the empowering official video of RISE.

We’ve also rounded up breast cancer research on how metastasis formation in breast cancer follows circadian rhythm dynamics and the use of immunogradient computational indicators to predict the overall survival of breast cancers. Find out how cancer cells shape shift, plus why some tumours are more resistant to NK killer cells and a treatment breakthrough for tumours in the animations below.

Cancer cells: Shape shifters and sleek movers

Using advanced technology, scientists have been able to demonstrate how cancer cells change shapes and moving styles to migrate from one area of the human body to the other and invade healthy tissues.

How do natural killer cells target cancer?

Watch this animation and learn about INmune Bio’s research, which focuses on the signals needed to transition NK cells from rest to lytic function – and why some tumours are more resistant to NK killing.

Immunogradient – Computational biomarkers of anti-tumour responses

Immunogradient computational indicators, based on automated grid-based extraction of the tumour-stroma interface zone from digital immunohistochemistry images, can be used to compute tumour-infiltrating lymphocytes’ density profiles and predict the overall survival of hormone receptor-positive breast cancer and colorectal cancer patients.

How does the small molecule AGX51 cause the degradation of ID proteins?

Together with Angiogenex, Inc. Dr Robert Benezra, Member of the Cancer Biology and Genetics Program at Memorial Sloan Kettering Cancer Center, has identified a small molecule, AGX51, that inhibits ID proteins and disrupts the cellular pathways by which cancers repropagate. AGX51 could therefore be an important potential new anti-tumour therapy.